<HashMap><database>iProX</database><scores/><additional><omics_type>Proteomics</omics_type><submitter>Xiangyun Gai</submitter><species>Rattus Norvegicus</species><full_dataset_link>http://www.iprox.org/page/project.html?id=IPX0017397000</full_dataset_link><submitter_email>2015002@qhmu.edu.cn</submitter_email><submitter_affiliation>Qinghai Minzu University</submitter_affiliation><sample_protocol></sample_protocol><repository>iProX</repository><data_protocol></data_protocol><pubmed_abstract>Hypoxic pulmonary hypertension (HPH) is a progressive vascular disease characterized by an abnormal increase in pulmonary arterial pressure resulting from pulmonary vasoconstriction and pulmonary vascular remodeling (PVR). Excessive proliferation and migration of pulmonary artery smooth muscle cells (PASMCs) are key drivers of PVR. &lt;i>Caragana jubata&lt;/i> (Pall.) Poir. (&lt;i>C. jubata&lt;/i>), known as "zuomaoxing" in Tibetan medicine, is traditionally used to treat blood-related disorders. However, the potential preventive and therapeutic effects of &lt;i>C. jubata&lt;/i> on HPH remain unclear. Here, we integrated in vivo pharmacology, serum pharmacochemistry, PASMC assays, DARTS-MS chemoproteomics, and pathway validation to investigate the effects of &lt;i>C. jubata&lt;/i> ethanol extract (ECJ) on HPH-associated PVR and the effects of a serum-exposed candidate component on CoCl&lt;sub>2&lt;/sub>-induced PASMC activation. In HPH rats, ECJ reduced mean pulmonary arterial pressure and alleviated right ventricular hypertrophy and PVR. Serum pharmacochemistry detected 47 ECJ-derived serum-exposed features, including one prototype putatively annotated as ginkgolide J. Ginkgolide J attenuated CoCl&lt;sub>2&lt;/sub>-induced PASMC proliferation, Ki-67 positivity, and migration without significantly affecting PASMC viability. DARTS-MS identified 1235 ginkgolide J-associated protease-susceptibility candidate proteins, and pathway validation indicated that ginkgolide J suppressed CoCl&lt;sub>2&lt;/sub>-induced MEK1/ERK1/2 activation. These findings suggest that ECJ has potential value against HPH-associated PVR and that ginkgolide J is a candidate anti-proliferative compound in PASMCs.</pubmed_abstract><pubmed_title>Serum Pharmacochemistry-Guided DARTS-MS Profiling Reveals Potential Mechanisms of &amp;lt;i&amp;gt;Caragana jubata&amp;lt;/i&amp;gt; Against Hypoxic Pulmonary Hypertension.</pubmed_title><pubmed_authors>Hu Jiacheng J, Qiao Yujie Y, Lei Gaoxiang G, Gai Xiangyun X, Xia Qingqing Q, Hu Qiuqin Q, Sun Haotian H, Wang Hongmai H, Li Zhanqiang Z, Zhao Yuefu Y, Wang Jinyu J</pubmed_authors></additional><is_claimable>false</is_claimable><name>DARTS-MS chemoproteomic profiling of ginkgolide J-associated protease-susceptibility candidate proteins in rat PASMC lysates</name><description>This dataset contains DIA-MS raw files and processed DIA-NN results from a DARTS-MS chemoproteomic experiment designed to identify ginkgolide J-associated protease-susceptibility candidate proteins in primary rat pulmonary artery smooth muscle cell (PASMC) lysates. The experiment included three groups with three biological replicates per group: DMSO vehicle control, protease-only group, and ginkgolide J plus protease group. PASMC protein lysates in the ginkgolide J plus protease group were incubated with ginkgolide J at 25 μM before limited proteolysis with Pronase E. DARTS-MS was used as a target-discovery chemoproteomic approach to detect ligand-associated changes in protease susceptibility rather than conventional steady-state protein expression changes.</description><dates><publication>Mon May 25 00:00:00 GMT+01:00 2026</publication></dates><accession>PXD078800</accession><cross_references><TAXONOMY>10116</TAXONOMY><pubmed>42450088</pubmed></cross_references></HashMap>